6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2024

Commission File Number: 001-39374

Inventiva S.A. (Translation of registrant's name into English)

50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ]

On November 20, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated November 20, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EdgarFiling

EXHIBIT 99.1

Statement of total voting rights and shares forming the company’s share capital as of November4, 2024

Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com

1. The total number of gross (or “theoretical”) votingrights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, thisnumber is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have beensuspended.

2. The total number of net (or “exercisable at aShareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended,i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properlyinformed .

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisionsof the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this pressrelease are forward-looking statements.

These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinicalprograms and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, includingthe ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, clinical trial data releases and publications, the information,insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates,including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinicaland clinical development plans, the expected benefit of having received Breakthrough Therapy Designation, including its impact on thedevelopment and review timeline of Inventiva’s product candidates, the potential development of and regulatory pathway for odiparcil,and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecastsand estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”,“intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”,“could”, “might”, “should”, “designed”, “hopefully”, “target”,“potential”, “opportunity”, “possible”, “aim”, and “continue” and similarexpressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statementsthat are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statementsand involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materiallyfrom those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyondInventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be availableon their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive thenecessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expectedtimeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievementsexpressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva cannotprovide assurance on the impacts of the S uspected Unexpected Serious Adverse Reaction (SUSAR) on enrollmentor the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stagecompany with no approved products and no historical product revenues , Inventiva has incurred significant losses since inception,Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capitalto finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or moreof its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities andmay be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions,Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization ofcurrent and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future resultsand the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidateclaims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holdsand/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan forlanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventivaand its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacyto the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients inclinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be mademore difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidatesmay cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercialpotential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinicaldevelopment programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopoliticalevents, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollmentand completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israeland Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, risinginterest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representationsare made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements,forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of theseforward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autoritédes Marchés Financiers on April 3, 2024 as amended on October 14, 2024, and the Annual Report on Form 20-F for the year ended December31, 2023, filed with the Securities and Exchange Commission on April 3, 2024, and the Half-Year Report for the six months ended June 30,2024 on Form 6-K filed with the SEC on October 15, 2024. Other risks and uncertainties of which Inventiva is not currently aware may alsoaffect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is underno obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for anyconsequences arising from the use of any of the above statements.

Attachment

• Inventiva - PR - number of shares and voting rights as at 04 Nov. 2024 - EN (https://ml-eu.globenewswire.com/Resource/Download/92ef9784-f8ca-4c67-b090-c8fd2a5ea9dc)